Loading
ADRM1 (Proteasomal ubiquitin receptor ADRM1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.
Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair.
Open Targets scores its association with cancer at 0.65 (direct and indirect evidence; datatypes clinical 0.99, literature 0.93, genetic association 0.00, somatic mutation 0.23, animal model 0.26).
In plain words · ADRM1 (Proteasomal ubiquitin receptor ADRM1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.
ADRM1 (Proteasomal ubiquitin receptor ADRM1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.
Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins.
No product in this corpus aims at ADRM1 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA ADRM1: RNA tissue enhanced (skeletal muscle 376 nTPM); high antibody staining in 23 normal tissues; highest cancer staining thyroid cancer (3 of 3 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Multiple myeloma, Lymphoma); Open Targets associates it with 2 specific cancer types at or above 0.5 (plasma cell myeloma, mantle cell lymphoma). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas ADRM1 tissue; Open Targets ENSG00000130706 associations
First described 1994. Earliest sequence paper UniProt cites for the protein: Shimada et al, Cancer Res, 1994, "Molecular cloning and characterization of the complementary DNA of an M(r) 110,000 antigen expressed by human gastric carcinoma cells and upregulated by gamma-interferon". Source.
Sources: HGNC HGNC:15759 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q16186 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000130706 (association with cancer (MONDO_0004992) 0.65; per-cancer scores at or above 0.5: plasma cell myeloma 0.61, non-Hodgkin lymphoma 0.57, mantle cell lymphoma 0.54 (GraphQL API, CC0))
Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair. Within the complex, functions as a proteasomal ubiquitin receptor. Engages and activates 19S-associated deubiquitinases UCHL5 and PSMD14 during protein degradation. UCHL5 reversibly associate with the 19S regulatory particle whereas PSMD14 is an intrinsic subunit of the proteasome lid subcomplex. Location: Cytoplasm; Nucleus (UniProt). Locus 20q13.33 (HGNC).
RNA: tissue enhanced (skeletal muscle 376 nTPM), detected in all normal tissues.
Medium: Adipose tissue, Bone marrow, Breast, Bronchus, Epididymis, Fallopian tube, Hippocampus, Liver.
Medium only: breast cancer, glioma, lymphoma.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"ADRM1" OR ABSTRACT:"ADRM1" OR TITLE:"ADRM1 26S proteasome ubiquitin receptor" OR ABSTRACT:"ADRM1 26S proteasome ubiquitin receptor" OR TITLE:"Proteasomal ubiquitin receptor ADRM1" OR ABSTRACT:"Proteasomal ubiquitin receptor ADRM1" OR TITLE:"GP110" OR ABSTRACT:"GP110" OR TITLE:"Rpn13" OR ABSTRACT:"Rpn13" OR TITLE:"ARM1" OR ABSTRACT:"ARM1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ADRM1, not a curated reading list.